TIDMABC

RNS Number : 4391A

ABCAM Plc

02 April 2012

 
 For immediate release   2 April 2012

ABCAM PLC

("Abcam" or "the Company")

Total Voting Rights - Voting Rights and Capital

In conformity with 5.6.1 of the Disclosure and Transparency Rules, the Company notifies the market of the following: The Company's issued share capital consists of 183,620,579 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury. The above figure of 183,620,579 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

Date of Notification: 2 April 2012

For further information please contact:

 
 Abcam                                        + 44 (0) 1223 696000 
 Jonathan Milner, Chief Executive Officer 
 Jeff Iliffe, Chief Financial Officer 
  www.abcamplc.com 
 
 Numis Securities - Nominated Advisor 
  and Joint Broker                            + 44 (0) 20 7260 1000 
 Michael Meade / Nick Westlake - Nominated 
  Adviser 
 James Black - Corporate Broking 
 
 Peel Hunt LLP - Joint Broker 
 Andy Crossley - Corporate Broking            + 44 (0) 20 7418 8900 
 
 Buchanan Communications                      + 44 (0) 20 7466 5000 
 Mark Court / Jessica Fontaine

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China), allowing it to serve a global customer base in over 85 countries. Abcam employs over 340 staff across its six operating companies.

Abcam now has an online catalogue of over 89,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRWGUMGWUPPURU

Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abcam Charts.
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abcam Charts.